Low levels of 25-hydroxy vitamin D are independently associated with the risk of bacterial infection in cirrhotic patients

Clinical and Translational Gastroenterology

Volumn 5, Issue , 2014, Pages

  Anty, Rodolphe ^a,b,c   Tonohouan, M ^a   Ferrari Panaia, P ^b   Piche, T ^b,c,d   Pariente, A ^e   Anstee, Q M ^f   Gual, P ^a,c   Tran, A ^a,b,c  

^a INSERM   (France)

^b UNIVERSITY HOSPITAL OF NICE   (France)

^c UNIVERSITÉ CÔTE D'AZUR   (France)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^e CENTRE HOSPITALIER DE PAU   (France)

^f NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALANINE AMINOTRANSFERASE; C REACTIVE PROTEIN;

ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; BACTERIAL PERITONITIS; BONE INFECTION; CHILD PUGH SCORE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HEPATITIS C; HUMAN; IMMUNOASSAY; INFECTION RISK; LIVER CIRRHOSIS; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; SKIN INFECTION; URINARY TRACT INFECTION; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; COHORT ANALYSIS; CONTROLLED STUDY; FOLLOW UP; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE COCCI; HOSPITAL PATIENT; MORTALITY; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PREDICTION; PROSPECTIVE STUDY; SEASONAL VARIATION;

EID: 84901776382     PISSN: None     EISSN: 2155384X     Source Type: Journal    
DOI: 10.1038/ctg.2014.6     Document Type: Article

References (58)

1. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-281.
2. Baeke F, Takiishi T, Korf H et al. Vitamin D: modulator of the immune system. Curr Opin Pharmacol 2010; 10: 482-496.
3. Bikle DD. Vitamin D regulation of immune function. Vitam Horm 2011; 86: 1-21.
4. Zittermann A, Iodice S, Pilz S et al. Vitamin D deficiency and mortality risk in the general population: a meta-analysis of prospective cohort studies. Am J Clin Nutr 2012; 95: 91-100.
5. Rejnmark L, Avenell A, Masud T et al. Vitamin D with calcium reduces mortality: patient level pooled analysis of 70, 528 patients from eight major vitamin D trials. J Clin Endocrinol Metab 2012; 97: 2670-2681.
6. Bjelakovic G, Gluud LL, Nikolova D et al. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev. 2011 CD007470.
7. Moromizato T, Litonjua AA, Braun AB et al. Association of low serum 25-hydroxyvitamin D levels and sepsis in the critically III. Crit Care Med 2013; 42: 97-107.
8. Yamshchikov AV, Desai NS, Blumberg HM et al. Vitamin D for treatment and prevention of infectious diseases: a systematic review of randomized controlled trials. Endocr Pract 2009; 15: 438-449.
9. Trepo E, Ouziel R, Pradat P et al. Marked 25-hydroxyvitamin D deficiency is associated with poor prognosis in patients with alcoholic liver disease. J Hepatol 2013; 1: 00203-1.
10. Putz-Bankuti C, Pilz S, Stojakovic T et al. Association of 25-hydroxyvitamin D levels with liver dysfunction and mortality in chronic liver disease. Liver Int. 2012; 32: 845-851.
11. Arvaniti V, D'Amico G, Fede G et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010; 139: 1246-1256.
12. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53: 397-417.
13. Runyon BA. Management of adult patients with ascites due to cirrhosis: update 2012. Hepatology 2013; 49: 2087-2107.
14. Fagiuoli S, Colli A, Bruno R et al. Management of infections in cirrhotic patients: report of a Consensus Conference. Dig Liver Dis 2014; 46: 204-212.
15. Fernandez J, Acevedo J, Castro M et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 2012; 55: 1551-1561.
16. Bajaj JS, O'Leary JG, Reddy KR et al. Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of endstage liver disease (NACSELD) experience. Hepatology 2012; 56: 2328-2335.
17. Barchetta I, Carotti S, Labbadia G et al. Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. Hepatology 2012; 56: 2180-2187.
18. Petta S, Camma C, Scazzone C et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 2010; 51: 1158-1167.
19. Petta S, Ferraro D, Camma C et al. Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C. Antivir Ther 2012; 17: 823-831.
20. Baur K, Mertens JC, Schmitt J et al. The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated-interferon/ribavirin-based therapy in chronic hepatitis C patients. Antivir Ther 2012; 17: 541-547.
21. Baur K, Mertens JC, Schmitt J et al. Combined effect of 25-OH vitamin D plasma levels and genetic vitamin D receptor (NR 1I1) variants on fibrosis progression rate in HCV patients. Liver Int 2012; 32: 635-643.
22. Lange CM, Bibert S, Kutalik Z et al. A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C. PLoS One 2012; 7: e40159.
23. Lange CM, Bojunga J, Ramos-Lopez E et al. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol 2011; 54: 887-893.
24. Falleti E, Bitetto D, Fabris C et al. Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C. Hepatology 2012; 56: 1641-1650.
25. Bitetto D, Fattovich G, Fabris C et al. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology 2011; 53: 1118-1126.
26. Abu-Mouch S, Fireman Z, Jarchovsky J et al. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naive patients. World J Gastroenterol 2011; 17: 5184-5190.
27. Kitson MT, Dore GJ, George J et al. Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. J Hepatol 2013; 58: 467-472.
28. Targher G, Bertolini L, Scala L et al. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2007; 17: 517-524. (Pubitemid 47176859)
29. Kwok RM, Torres DM, Harrison SA. Vitamin D and NAFLD: Is it more than just an association? Hepatology 2013; 16: 26390.
30. Farnik H, Bojunga J, Berger A et al. Low vitamin D serum concentration is associated with high levels of hepatitis B virus (HBV) replication in chronically infected patients. Hepatology 2013; 58: 1270-1276.
31. Miroliaee A, Nasiri-Toosi M, Khalilzadeh O et al. Disturbances of parathyroid hormonevitamin D axis in non-cholestatic chronic liver disease: a cross-sectional study. Hepatol Int 2010; 4: 634-640.
32. Malham M, Jorgensen SP, Ott P et al. Vitamin D deficiency in cirrhosis relates to liver dysfunction rather than aetiology. World J Gastroenterol 2011; 17: 922-925.
33. Bitetto D, Fabris C, Falleti E et al. Vitamin D and the risk of acute allograft rejection following human liver transplantation. Liver Int 2010; 30: 417-444.
34. Reese PP, Bloom RD, Feldman HI et al. Changes in vitamin D binding protein and vitamin D concentrations associated with liver transplantation. Liver Int 2012; 32: 287-296.
35. Abbott-Johnson W, Kerlin P, Clague A et al. Relationships between blood levels of fat soluble vitamins and disease etiology and severity in adults awaiting liver transplantation. J Gastroenterol Hepatol 2011; 26: 1402-1410.
36. Venu M, Martin E, Saeian K et al. High prevalence of vitamin A deficiency and vitamin D deficiency in patients evaluated for liver transplantation. Liver Transpl 2013; 14: 23646.
37. Gitto S, Lorenzini S, Biselli M et al. Allocation priority in non-urgent liver transplantation: An overview of proposed scoring systems. Dig Liver Dis 2009; 41: 700-706.
38. Cholongitas E, Papatheodoridis GV, Vangeli M et al. Systematic review: The model for end-stage liver disease-should it replace Child-Pugh's classification for assessing prognosis in cirrhosis? Aliment Pharmacol Ther 2005; 22: 1079-1089. (Pubitemid 41779515)
39. Cholongitas E, Theocharidou E, Goulis J et al. Review article: the extra-skeletal effects of vitamin D in chronic hepatitis C infection. Aliment Pharmacol Ther 2012; 35: 634-646.
40. Braun A, Chang D, Mahadevappa K et al. Association of low serum 25-hydroxyvitamin D levels and mortality in the critically ill. Crit Care Med 2011; 39: 671-677.
41. Kerschbaum J, Vychytil A, Lhotta K et al. Treatment with oral active vitamin D is associated with decreased risk of peritonitis and improved survival in patients on peritoneal dialysis. PLoS One 2013; 8: e67836.
42. Zhang C, Zhao L, Ma L et al. Vitamin D status and expression of vitamin D receptor and LL-37 in patients with spontaneous bacterial peritonitis. Dig Dis Sci 2012; 57: 182-188.
43. Liu PT, Stenger S, Li H et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006; 311: 1770-1773.
44. Gombart AF. The vitamin D-antimicrobial peptide pathway and its role in protection against infection. Future Microbiol 2009; 4: 1151-1165.
45. White JH. Vitamin D signaling, infectious diseases, and regulation of innate immunity. Infect Immun 2008; 76: 3837-3843.
46. Tarr AW, Urbanowicz RA, Ball JK. The role of humoral innate immunity in hepatitis C virus infection. Viruses 2012; 4: 1-27.
47. Goel A, Gupta M, Aggarwal R. Gut microbiota and liver disease. J Gastroenterol Hepatol 2014; doi:10.1111/jgh.12556 (in press).
48. Holt PR, Arber N, Halmos B et al. Colonic epithelial cell proliferation decreases with increasing levels of serum 25-hydroxy vitamin D. Cancer Epidemiol Biomarkers Prev 2002; 11: 113-119. (Pubitemid 34118320)
49. Kong J, Zhang Z, Musch MW et al. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am J Physiol Gastrointest Liver Physiol 2008; 294: G208-G216.
50. Ding N, Yu RT, Subramaniam N et al. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell 2013; 153: 601-613.
51. Roth CL, Elfers CT, Figlewicz DP et al. Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and Toll-like receptor activation. Hepatology 2012; 55: 1103-1111.
52. Bajaj JS, Heuman DM, Hylemon PB et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 2013; 60: 940-947.
53. Ponda MP, Breslow JL. Vitamin D3 repletion in chronic kidney disease stage 3: effects on blood endotoxin activity, inflammatory cytokines, and intestinal permeability. Ren Fail 2013; 35: 497-503.
54. Ly NP, Litonjua A, Gold DR et al. Gut microbiota, probiotics, and vitamin D: interrelated exposures influencing allergy, asthma, and obesity? J Allergy Clin Immunol 2011; 127: 1087-1094.
55. Lade A, Noon LA, Friedman SL. Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer. Curr Opin Oncol 2014; 26: 100-107.
56. Rode A, Fourlanos S, Nicoll A. Oral vitamin D replacement is effective in chronic liver disease. Gastroenterol Clin Biol. 2010; 34: 618-620.
57. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009; 51: 237-267.
58. Murdoch DR, Slow S, Chambers ST et al. Effect of vitamin D3 supplementation on upper respiratory tract infections in healthy adults: the VIDARIS randomized controlled trial. JAMA 2012; 308: 1333-1339.